NHLBI TOPMed: HyperGEN - Genetics of Left Ventricular (LV) Hypertrophy

The Hypertension Genetic Epidemiology Network Study (HyperGEN) - Genetics of Left Ventricular (LV) Hypertrophy is a familial study aimed to understand genetic risk factors for LV hypertrophy by conducting genetic studies of continuous traits from echocardiography exams. The originating HyperGEN study aimed to understand genetic risk factors for hypertension. Data from detailed clinical exams as well as genotyping data for linkage studies, candidate gene studies and GWAS have been collected and is shared between HyperGEN and the ancillary HyperGEN - Genetics of LV Hypertrophy study.]]>
TOPMed Whole Genome Sequencing Methods: Freeze 8TOPMed Whole Genome Sequencing Methods: Freeze 9HyperGEN recruited 470 multiply-affected population-based hypertensive AA sibships (N=1224 siblings) from 1996-1999. HyperGEN probands were ascertained by early onset hypertension (i.e., before 60 years); to participate, they had to have at least one hypertensive sibling who was also willing to participate. Hypertension was defined according to antihypertensive treatment or BP (systolic BP ≥140 or diastolic BP ≥90 measured on at least at two time points); Type 1 diabetes and renal failure were exclusion criteria. The HyperGEN study extended recruitment to include all offspring (n=546) of the proband and his/her siblings during the second 5-year funding period. HyperGEN also recruited participants randomly selected from the source cohorts where the families were ascertained to represent population allele frequencies; 414 African American participants were recruited randomly. In total, ~2,200 African-American participants were examined and gave permission for DNA testing and sharing from sites in Birmingham, AL and Winston-Salem, NC. Of those ~2000 have data recorded from an echocardiography exam and were included in the TOPMed study of LV hypertrophy and related traits.]]>
The parent HyperGEN study includes both black and white participants. The HyperGEN-Genetics of LV Hypertrophy TopMED supplement study includes genotype and phenotype data from 2104 black participants, the majority of them with echocardiographic data.]]>